SEARCH

SEARCH BY CITATION

References

  • 1
    Toribio RE . Diagnosing equine pars intermedia dysfunction: Are we there yet? J Vet Intern Med 2005;19:145146.
  • 2
    McCue PM . Equine Cushing's disease. Vet Clin North Am Equine Pract 2002;18:533543.
  • 3
    Love S . Equine Cushing's disease. Br Vet J 1993;149:139153.
  • 4
    Beech J , Garcia M . Hormonal response to thyrotropin-releasing hormone in healthy horses and in horses with pituitary adenoma. Am J Vet Res 1985;46:19411943.
  • 5
    Eiler H , Oliver JW , Andrews FM , et al. Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma. J Am Vet Med Assoc 1997;211:7981.
  • 6
    Keen JA , McLaren M , Chandler KJ , McGorum BC . Biochemical indices of vascular function, glucose metabolism and oxidative stress in horses with equine Cushing's disease. Equine Vet J 2004;36:226229.
  • 7
    Donaldson MT , McDonnell SM , Schanbacher BJ , et al. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J Vet Intern Med 2005;19:217222.
  • 8
    McGowan CM , Frost R , Pfeiffer DU , Neiger R . Serum insulin concentrations in horses with equine Cushing's syndrome: Response to a cortisol inhibitor and prognostic value. Equine Vet J 2004;36:295298.
  • 9
    Perkins GA , Lamb S , Erb HN , et al. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Vet J 2002;34:679685.
  • 10
    Davis JL , Kirk LM , Davidson GS , Papich MG . Effects of compounded and storage conditions on stability of pergolide mesylate. J Am Vet Med Assoc 2009;234:385389.
  • 11
    Dillman DA . Mail and Internet Surveys; The Tailored Design Method. 2nd ed. Hoboken NJ: Wiley; 2007.
  • 12
    Schott HC , Coursen CL , Eberhart SW , et al. The Michigan Cushing's project. In: Proceedings of the 47th Annual Convention of the American Association of Equine Practitioners; 2001:224.
  • 13
    Duncan JR , Prasse KW . Veterinary Laboratory Medicine, Clinical Pathology, 2nd ed. Ames, IA: Iowa State University Press; 1986:229234.
  • 14
    Couetil L , Paradis MR , Knoll J . Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med 1996;10:16.
  • 15
    Frank N , Andrews FM , Sommardahl CS , et al. Evaluation of the combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses. J Vet Intern Med 2006;20:987993.
  • 16
    Hillyer M , Taylor FGR , Mair TS , et al. Diagnosis of hyperadrenocorticism in the horse. Equine Vet Educ 1992;4:131134.
  • 17
    Dybdal NO , Hargreaves KM , Madigan JE , et al. Diagnostic testing for pituitary pars intermedia dysfunction in horses. J Am Vet Med Assoc 1994;204:627632.
  • 18
    Gribble DH . The endocrine system. In: Catcott EJ , Smithcors JF , eds. Equine Medicine and Surgery, 2nd ed. Wheaton, IL: American Veterinary Publications; 1972: 43357.
  • 19
    Heinrichs M , Baumgartner W , Capen CC . Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses. Vet Pathol 1990;27:41925.
  • 20
    Donaldson MT , LaMonte BH , Morresey P , et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). J Vet Intern Med 2002;16:742746.
  • 21
    McGowan CM , Neiger R . Efficacy of trilostane for the treatment of equine Cushing's syndrome. Equine Vet J 2003;35:414418.
  • 22
    Donaldson MT , Jorgensen AJ , Beech J . Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc 2004;224:11231127.
  • 23
    Dybdal N . Pituitary pars intermedia dysfunction (equine Cushing's-like disease) In: Robinson N , ed. Current Therapy in Equine Medicine, 4th ed. Philadelphia, PA: WB Saunders; 1997:449501.
  • 24
    Loeb WF , Capen CC , Johnson LE . Adenomas of the pars intermedia associated with hyperglycemia and glycosuria in two horses. Cornell Vet 1966;56:623639.
  • 25
    van der Kolk JH , Kalsbeek HC , van Garderen E , et al. Equine pituitary neoplasia: A clinical report of 21 cases (1990-1992). Vet Rec 1993;133:594597.
  • 26
    Eyre P , Elmes PJ , Strickland S . Corticosteroid-potentiated vascular responses of the equine digit: A possible pharmacologic basis for laminitis. Am J Vet Res 1979;40:135138.
  • 27
    van der Kolk JH WT , Kalsbeek HC , Breukink HJ . Laboratory diagnosis of equine pituitary pars intermedia adenoma. Domest Anim Endocrinol 1995;12:3539.
  • 28
    Schott HC . Pituitary pars intermedia dysfunction: Equine Cushing's disease. Vet Clin North Am 2002;18:237270.
  • 29
    Green EM , Hunt EL . Hypophyseal neoplasia in a pony. Compend Contin Educ Pract Vet 1985;7:S24957.
  • 30
    van der Kolk J . Equine Cushing's disease. Equine Vet Educ 1997;9:209214.
  • 31
    Aleman M , Watson JL , Williams DC , et al. Myopathy in horses with pituitary pars intermedia dysfunction (Cushing's disease). Neuromuscul Disord 2006;16:737744.
  • 32
    Field JR , Wolf C . Cushing's syndrome in a horse. Equine Vet J 1988;20:3014.
  • 33
    Cohen ND , Carter GK . Steroid hepatopathy in a horse with glucocorticoid-induced hyperadrenocorticism. J Am Vet Med Assoc 1992;200:16824.
  • 34
    Johnson SE , Scherding RG . Diseases of the liver and biliary tract. In: Birchard SJ , Scherding RG , eds. Saunders Manual of Small Animal Practice, 2nd ed. Philadelphia, PA: WB Saunders; 2000:82473.
  • 35
    Schott HC , Graves EA , Refsal KR , et al. Diagnosis and treatment of pituitary pars intermedia dysfunction (classical Cushing's disease) and metabolic syndrome (peripheral Cushing's syndrome) in horses. Proceedings of the 5th World World Cong Vet Derm 2005;5:159169.